Tag:
companion diagnostics
Latest Headlines
Latest Headlines
Agilent jumps into molecular diagnostics with $2.2B Dako deal
Denmark's Dako shows once again why molecular diagnostics are the life sciences segment to watch this year. Agilent Technologies ($A) has inked a deal to pay $2.2 billion for the cancer diagnostic tools company in a bid to boost its growth in the space.
Genomic Health, OncoMed to pursue companion diagnostics
Genomic Health and OncoMed Pharmaceuticals have an agreement to identify new biomarkers useful for future companion diagnostics that would go along with OncoMed's cancer drugs now in development.
Merck snags rights to Endocyte's ovarian cancer drug in $1B deal
Merck has scooped up worldwide rights to Endocyte's late-stage ovarian cancer drug in a billion-dollar deal.
Basiliea finds potential biomarker for personalized medicine
Basiliea has discovered a biomarker for its experimental cancer therapeutic with data presented at this year's American Association for Cancer Research annual meeting in Chicago.
Roche pressures Illumina with higher, $6.7B offer
Swiss drug giant Roche has upped its offer for the San Diego-based gene sequencing company Illumina to nearly $6.7 billion, or $51 a share.
Big trouble seen for targeted cancer drugs
Researchers have discovered that the genetic complexities of cancer could thwart current methods of matching a patient's tumor with targeted drugs.
Dako, Amgen in companion Dx pact
Over the past few months, we've profiled a number of companion diagnostics deals between big biopharmas and diagnostic companies. This week, Denmark's Dako reported it is working with Amgen...
Nodality, UCB Pharma ink multiyear companion diagnostics deal
South San Francisco personalized medicine/diagnostics startup Nodality has signed a multi-year collaborative deal with Belgium's UCB Pharma that will initially focus on possible companion diagnostics
Qiagen signs diagnostic biomarker deals
Qiagen , a Netherlands-based bioassay company, is developing new cancer biomarker assays after acquiring rights to genes and biomarkers. In agreements with Insight Genetics and Personal Genome
Roche gets key nod for targeted skin cancer drug en route to EU approval
A standout drug for "personalized" skin cancer treatment has gained a key endorsement from European regulators. Roche ( $RHHBY ) said that the European Medicines Agency backed the targeted melanoma
